Skip to main content
. 2022 Feb 18;14(4):1050. doi: 10.3390/cancers14041050

Figure 3.

Figure 3

Figure 3

(a) Samples colored according to the disease; (b) samples colored according to the HCL score; (c) samples colored according to the BRAF mutational status. Component principal analysis (CPA) projection (first versus second principal component). Each dot corresponds to a sample (cHCL n = 64, cHCL BRAFWT n = 8, vHCL/SDRPL n = 5, HCL-like NOS n = 9). Variables used: (percentage of expression + median of fluorescence of CD19, CD20, CD79b, FMC7, CD5, CD10, CD23, CD43, CD38, CD11c, CD103, CD123, CD25; percentage of abnormal cells on sample, percentage of abnormal cells compared to total lymphocytes). Variables factor map in the right corner. Ellipses represent confidence level for a concentration of 90%.